Do analysts recommend CNSP or PTPI?

CNS Pharmaceuticals currently has a consensus price target of $20.00, indicating a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CNSP or PTPI more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Petros Pharmaceuticals N/A -78.22% -23.50%

Do analysts rate AIXC or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, AIXC or CNSP?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is AIXC or CNSP more profitable?

CNS Pharmaceuticals' return on equity of -238.68% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% CNS Pharmaceuticals N/A -238.68% -166.30%

Is CNSP or LITS more profitable?

Lite Strategy's return on equity of -90.81% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Lite Strategy N/A -90.81% -89.33%

Do analysts prefer CNSP or TXMD?

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CNS Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, SKYE or CNSP?

Skye Bioscience is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.44 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is SKYE or CNSP more profitable?

Skye Bioscience's return on equity of -217.27% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -217.27% -162.39% CNS Pharmaceuticals N/A -238.68% -166.30%

CNS Pharmaceuticals (CNSP) Competitors

$4.17 -0.12 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 -0.19 (-4.44%)

As of 04:10 PM Eastern

Compare

CNSP vs. PTPI, AIXC, LITS, TXMD, and SKYE

Should you buy CNS Pharmaceuticals stock or one of its competitors? MarketBeat compares CNS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CNS Pharmaceuticals include Petros Pharmaceuticals (PTPI), Qualigen Therapeutics (AIXC), Lite Strategy (LITS), TherapeuticsMD (TXMD), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A

CNS Pharmaceuticals has a beta of 3.06, suggesting that its share price is 206% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CNS Pharmaceuticals currently has a consensus price target of $20.00, indicating a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

CNS Pharmaceuticals' return on equity of -238.68% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Qualigen Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market.

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

In the previous week, Qualigen Therapeutics had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for CNS Pharmaceuticals. Qualigen Therapeutics' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
CNS Pharmaceuticals	Neutral

Summary

CNS Pharmaceuticals beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Lite Strategy?

CNS Pharmaceuticals (NASDAQ:CNSP) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

CNS Pharmaceuticals has higher earnings, but lower revenue than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Lite Strategy	$65.30M	0.45	-$15.94M	-$1.60	N/A

CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market. Comparatively, Lite Strategy has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

CNS Pharmaceuticals currently has a consensus target price of $20.00, indicating a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe CNS Pharmaceuticals is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.4% of Lite Strategy shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Lite Strategy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lite Strategy's return on equity of -90.81% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Lite Strategy	N/A	-90.81%	-89.33%

In the previous week, Lite Strategy had 5 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 5 mentions for Lite Strategy and 0 mentions for CNS Pharmaceuticals. Lite Strategy's average media sentiment score of 0.57 beat CNS Pharmaceuticals' score of 0.00 indicating that Lite Strategy is being referred to more favorably in the news media.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Lite Strategy	Positive

Summary

Lite Strategy beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to TherapeuticsMD?

CNS Pharmaceuticals (NASDAQ:CNSP) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
TherapeuticsMD	$3.02M	7.70	-$570K	$0.06	33.50

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 379.62%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe CNS Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has a net margin of 5.34% compared to CNS Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
TherapeuticsMD	5.34%	0.32%	0.23%

CNS Pharmaceuticals has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Skye Bioscience had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for CNS Pharmaceuticals. Skye Bioscience's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Skye Bioscience	Neutral
CNS Pharmaceuticals	Neutral

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Skye Bioscience is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Skye Bioscience has a beta of 2.95, indicating that its share price is 195% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.06, indicating that its share price is 206% more volatile than the broader market.

Skye Bioscience currently has a consensus target price of $8.50, indicating a potential upside of 1,151.84%. CNS Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 379.62%. Given Skye Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Skye Bioscience is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Skye Bioscience's return on equity of -217.27% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Summary

Skye Bioscience beats CNS Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.09M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-0.14	20.68	25.17	24.00
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.57	8.26	10.76	6.41
Net Income	-$15.85M	$23.91M	$3.56B	$337.14M
7 Day Performance	-7.95%	3.05%	1.37%	-0.48%
1 Month Performance	-23.06%	2.40%	0.81%	0.49%
1 Year Performance	-54.16%	56.35%	30.53%	28.16%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	2.4036 of 5 stars	$4.17 -2.8%	$20.00 +379.6%	-52.9%	$6.09M	N/A	N/A	5
PTPI Petros Pharmaceuticals	N/A	$0.01 -1.6%	N/A	-80.7%	$187K	$5.11M	N/A	20	News Coverage Gap Up
AIXC Qualigen Therapeutics	0.1435 of 5 stars	$1.49 +8.8%	N/A	N/A	$27.72M	N/A	N/A	50	Positive News High Trading Volume
LITS Lite Strategy	0.8445 of 5 stars	$0.92 +14.9%	N/A	N/A	$27.24M	$65.30M	N/A	100	News Coverage High Trading Volume
TXMD TherapeuticsMD	0.7805 of 5 stars	$2.29 +0.4%	N/A	+80.2%	$26.39M	$3.02M	38.17	420	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, AIXC, LITS, TXMD, and SKYE

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Qualigen Therapeutics?

Summary

How does CNS Pharmaceuticals compare to Lite Strategy?

Summary

How does CNS Pharmaceuticals compare to TherapeuticsMD?

Summary

How does CNS Pharmaceuticals compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, AIXC, LITS, TXMD, and SKYE

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Does the media prefer CNSP or PTPI?

Which has higher earnings and valuation, CNSP or PTPI?

Which has more risk and volatility, CNSP or PTPI?

Do institutionals & insiders believe in CNSP or PTPI?

Do analysts recommend CNSP or PTPI?

Is CNSP or PTPI more profitable?

Summary

How does CNS Pharmaceuticals compare to Qualigen Therapeutics?

Is AIXC or CNSP more profitable?

Which has more risk and volatility, AIXC or CNSP?

Do analysts rate AIXC or CNSP?

Do insiders & institutionals hold more shares of AIXC or CNSP?

Which has preferable earnings & valuation, AIXC or CNSP?

Does the media refer more to AIXC or CNSP?

Summary

How does CNS Pharmaceuticals compare to Lite Strategy?

Which has preferable earnings & valuation, CNSP or LITS?

Which has more risk & volatility, CNSP or LITS?

Do analysts recommend CNSP or LITS?

Do institutionals & insiders have more ownership in CNSP or LITS?

Is CNSP or LITS more profitable?

Does the media prefer CNSP or LITS?

Summary

How does CNS Pharmaceuticals compare to TherapeuticsMD?

Do institutionals & insiders hold more shares of CNSP or TXMD?

Which has better earnings & valuation, CNSP or TXMD?

Do analysts prefer CNSP or TXMD?

Is CNSP or TXMD more profitable?

Which has more risk & volatility, CNSP or TXMD?

Does the media refer more to CNSP or TXMD?

Summary

How does CNS Pharmaceuticals compare to Skye Bioscience?

Does the media prefer SKYE or CNSP?

Do insiders & institutionals have more ownership in SKYE or CNSP?

Which has better earnings & valuation, SKYE or CNSP?

Which has more volatility & risk, SKYE or CNSP?

Do analysts prefer SKYE or CNSP?

Is SKYE or CNSP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools